Teva acquires Emalex for $700m to boost neuroscience pipeline
Teva Pharmaceutical Industries Ltd. acquired Emalex Biosciences for $700 million to strengthen its neuroscience pipeline with ecopipam, a treatment for Tourette syndrome. The deal includes up to $200 million in commercial milestones and royalties. Ecopipam has received FDA Orphan Drug and Fast Track designations, with an NDA submission expected in the second half of 2026.
*this image is generated using AI for illustrative purposes only.
Teva Pharmaceutical Industries Ltd. has acquired Emalex Biosciences for $700 million to strengthen its late-stage neuroscience pipeline with ecopipam. The acquisition advances Teva's Pivot to Growth strategy by adding a first-in-class selective dopamine D1 receptor antagonist designed to treat pediatric Tourette syndrome. The deal includes potential commercial milestone payments of up to $200 million and net sales-based royalties upon commercialization, subject to regulatory approval.
Paragon Biosciences, the creator of Emalex Biosciences, announced the closing of the sale, reinforcing its ability to build innovative biotechnology companies. Emalex was developed to address central nervous system disorders, following the success of other Paragon-founded companies such as Harmony Biosciences. Jeff Aronin, founder and CEO of Paragon Biosciences, stated that the transaction demonstrates the power of focused innovation to address underserved diseases.
Financial Details
The transaction structure includes an upfront payment and future contingent payments based on regulatory and commercial milestones.
| Payment Component | Amount |
|---|---|
| Upfront Consideration | $700 million |
| Commercial Milestones | Up to $200 million |
| Royalties | Net sales-based |
Clinical Profile and Safety
Ecopipam has received Orphan Drug and Fast Track designations from the FDA. A U.S. New Drug Application (NDA) submission is anticipated in the second half of 2026. Phase 3 data for ecopipam were recently published in JAMA Neurology, demonstrating statistical significance for the primary efficacy endpoint compared to placebo (p = 0.0084).
The Phase 3 study evaluated time to relapse for pediatric patients stable and responding to ecopipam who were then randomized to ecopipam or placebo. Ecopipam was generally well-tolerated in the study. The most common adverse events related to ecopipam therapy were somnolence (10.2%), insomnia (7.4%), anxiety (6.0%), fatigue (5.6%), and headache (5.1%).
Richard Francis, President and Chief Executive Officer of Teva, stated that the acquisition reflects the company's strategy to advance its innovative pipeline through focused, capital-efficient business development. Eric Messner, chief executive officer of Emalex Biosciences, emphasized the team's focus on rigorous clinical execution and addressing a significant unmet need.
How will Teva integrate ecopipam into its existing commercial infrastructure to maximize market penetration upon approval?
What are the potential risks to the anticipated 2026 NDA submission given the competitive landscape for Tourette syndrome treatments?
How might the $200 million in commercial milestone payments impact Teva's cash flow and capital allocation in the coming years?
16
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
